Amarin Corp Plc (AMRN)

[couldbebetter]

The Japanese were the first to develop EPA as a medication. There are many Japanese studies that show its benefits. The problem, as you point out so well, is that the Japanese have a very high EPA level to begin with. To prove the true benefit of EPA on CVD for a western population, with its poor diet, has never been done, at least not in a major way.

Reduce-It results are likely to be far more important than most of us think. The clearer the results, the greater the value Vascepa will have as a CVD drug. Because the study is running longer than many of us thought it would is positive in many ways. I hope it answers the many important quetions so many of us have. "Only" 6 months to less than a year to find out. I bet BP is watching as intently as we are. I also wonder if perhaps a Japanese BP would want to buy AMRN to control the market.